

D1 (c) a nucleotide sequence comprising 289 or more contiguous nucleotides of SEQ ID NO:1;

(d) a complement of (c);

(e) a nucleotide sequence comprising 500 or more contiguous nucleotides of SEQ ID NO:1; and

(f) a complement of (e).

D2 37. (Once Amended) An expression vector comprising the nucleic acid molecule of claim 34.

38. (Once Amended) A host cell comprising the vector of claim 37.

D3 42. (Once Amended) Isolated DNA or RNA comprising 289 or more contiguous nucleotides of:

(a) SEQ ID NO:1; or

(b) a complement of SEQ ID NO:1.

D4 46. (Once Amended) An expression vector comprising the DNA or RNA of claim 42.

D5 48. (Once Amended) A host cell comprising the vector of claim 46.

D4 52. (Once Amended) An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) SEQ ID NO:46, SEQ ID NO:47, and SEQ ID NO:49;

(b) a complement of (a);

(c) a nucleotide sequence comprising at least 25 contiguous nucleotides of any one of SEQ ID NO:48, SEQ ID NO:50, and SEQ ID NO:51; and

(d) a complement of (c).

53. (Once Amended) An isolated nucleic acid molecule which comprises 40 or more

contiguous nucleotides of SEQ ID NO:1 and includes at least one single nucleotide polymorphism selected from the group consisting of:

- 06
- (a) an A at position 6684;
 - (b) a G at position 6684;
 - (c) a C at position 6991;
 - (d) a T at position 6991;
 - (e) a C at position 3176; and
 - (f) a T at position 3176.

54. (Once Amended) An isolated nucleic acid fragment of BAC RP11-0702C13 which comprises 289 or more contiguous nucleotides of SEQ ID NO:1.

07 56. (Once Amended) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- (a) SEQ ID NO:2;
 - (b) a nucleotide sequence encoding amino acid sequence SEQ ID NO:3;
 - (c) a complement of SEQ ID NO:2;
 - (d) a nucleotide sequence comprising 289 or more contiguous nucleotides of SEQ ID NO:2;
 - (e) a complement of (d);
 - (f) a nucleotide sequence comprising 500 or more contiguous nucleotides of SEQ ID NO:2;
 - (g) a complement of (f); and
 - (h) a nucleotide sequence which encodes 100 or more consecutive amino acids of SEQ ID NO:3.
-

08 59. (Once Amended) An expression vector comprising the nucleic acid molecule of claim 56.

60. (Once Amended) A host cell comprising the vector of claim 59.

D9 64. (Once Amended) Isolated DNA or RNA comprising 289 or more contiguous nucleotides of:

- (a) SEQ ID NO:2; or
- (b) a complement of SEQ ID NO:2.

D10 68. (Once Amended) An expression vector comprising the DNA or RNA of claim 64.

D11 70. (Once Amended) A host cell comprising the vector of claim 68.

D12 72. (Once Amended) The host cell according to claim 70 selected from the group consisting of a eukaryotic cell, a human cell and a prokaryotic cell.

REMARKS

Claims 34-42, 46, 48, 50, 52-54, 56-64, 68, 70, and 72 are pending in the application.

In this Amendment, claims 43-45, 47, 49, 51, 55, 65-67, 69, 71, and 73-74 have been cancelled without prejudice or disclaimer, solely for the purpose of expediting the patent application process in accordance with the PTO's Patent Business Goals, 65 Fed. Reg. 54603 (September 8, 2000). Applicants reserve the right to present these claims and the cancelled subject matter in a continuing application.

In addition, claims 34, 37-38, 42, 46, 48, 52-54, 56, 59-60, 64, 68, 70, and 72 have been amended for clarity, to more fully describe Applicants' invention, and to expedite the patent application process in accordance with the PTO's Patent Business Goals, 65 Fed. Reg. 54603 (September 8, 2000). No new matter has been introduced by the amended claims, which are fully supported by the specification, claims, and/or drawings of the application as filed.

For claims 34, 42, 54, 56, and 64, support for the recitation of "289 or more contiguous